122 related articles for article (PubMed ID: 2697592)
1. Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology.
Pileri A; Ferrero D; Massaia M; Dianzani U; Boccadoro M
Eur J Haematol Suppl; 1989; 51():30-4. PubMed ID: 2697592
[TBL] [Abstract][Full Text] [Related]
2. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
Millar BC; Bell JB; Barfoot R; Everard M
Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
[TBL] [Abstract][Full Text] [Related]
3. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of the escape phase of myeloma.
Joshua DE; Gibson J; Brown RD
Blood Rev; 1994 Mar; 8(1):13-20. PubMed ID: 8205006
[TBL] [Abstract][Full Text] [Related]
5. [Molecular analysis of multiple myeloma cells].
Yasuga Y; Hirosawa S
Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors in multiple myeloma].
Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A
Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219
[No Abstract] [Full Text] [Related]
7. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
8. Biology of plasma cells.
Chen-Kiang S
Best Pract Res Clin Haematol; 2005; 18(4):493-507. PubMed ID: 16026733
[TBL] [Abstract][Full Text] [Related]
9. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
10. Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.
Fosså A; Brandhorst D; Myklebust JH; Seeber S; Nowrousian MR
Exp Hematol; 1999 Nov; 27(11):1621-6. PubMed ID: 10560909
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma. Mechanisms of proliferation and neoplastic progression and their clinical implications].
Boccadoro M; Battaglio S; Dianzani U; Frieri R; Gallone G; Massaia M; Omedè P; Palumbo A; Pileri A
Haematologica; 1991 Jun; 76 Suppl 3():100-6. PubMed ID: 1752506
[No Abstract] [Full Text] [Related]
12. Ras oncogene mutation in multiple myeloma.
Neri A; Murphy JP; Cro L; Ferrero D; Tarella C; Baldini L; Dalla-Favera R
J Exp Med; 1989 Nov; 170(5):1715-25. PubMed ID: 2681517
[TBL] [Abstract][Full Text] [Related]
13. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma.
Matsuo Y; Drexler HG; Nishizaki C; Harashima A; Fukuda S; Kozuka T; Sezaki T; Orita K
Br J Haematol; 2000 Apr; 109(1):54-63. PubMed ID: 10848782
[TBL] [Abstract][Full Text] [Related]
14. Homing mechanisms in the biology of multiple myeloma.
Van Camp B; Van Riet I
Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
[TBL] [Abstract][Full Text] [Related]
15. The use of biological variables to predict outcome in multiple myeloma.
Davies FE; Jack AS; Morgan GJ
Br J Haematol; 1997 Dec; 99(4):719-25. PubMed ID: 9432013
[No Abstract] [Full Text] [Related]
16. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
17. [Immunodeficiency during plasmocytoma].
Indiveri F; Puppo F; Franceschini R; Barabino A
Pathologica; 1978; 70(1003-1004):239-49. PubMed ID: 683727
[No Abstract] [Full Text] [Related]
18. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation.
Sanal SM; Yaylaci M; Mangold KA; Pantazis CG
Cancer; 1996 Apr; 77(7):1298-302. PubMed ID: 8608506
[TBL] [Abstract][Full Text] [Related]
19. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
20. Host-related immunodeficiency in the development of multiple myeloma.
Dosani T; Mailankody S; Korde N; Manasanch E; Bhutani M; Tageja N; Roschewski M; Kwok M; Kazandjian D; Costello R; Burton D; Zhang Y; Liewehr D; Steinberg SM; Maric I; Landgren O
Leuk Lymphoma; 2018 May; 59(5):1127-1132. PubMed ID: 28792255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
